{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:09:26Z","timestamp":1784225366616,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation Research"],"published-print":{"date-parts":[[2026,7,17]]},"DOI":"10.1161\/circresaha.126.329279","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:00:17Z","timestamp":1784224817000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining Therapeutic Targets in Hypertension and Cardiometabolic Syndrome"],"prefix":"10.1161","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-5831","authenticated-orcid":true,"given":"Sepiso K.","family":"Masenga","sequence":"first","affiliation":[{"name":"Vanderbilt Institute for Global Health (S.K.M., A.K.), Vanderbilt University Medical Center, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-9359","authenticated-orcid":true,"given":"Annet","family":"Kirabo","sequence":"additional","affiliation":[{"name":"Vanderbilt Institute for Global Health (S.K.M., A.K.), Vanderbilt University Medical Center, Nashville, TN."},{"name":"Vanderbilt Center for Immunobiology (A.K.), Vanderbilt University Medical Center, Nashville, TN."},{"name":"Vanderbilt Institute for Infection, Immunology and Inflammation (A.K.), Vanderbilt University Medical Center, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-01019-y"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2005.04617.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88984"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2016.00003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2006.05836.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1101068"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25074035"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.10.007"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.325496"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081914"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01430-7"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","unstructured":"Dennis CJ He AZ Krishnaraj A Quan A Connelly KA Hess DA Verma S. The silent struggle: prevention of vascular aging as a novel paradigm for GLP-1 receptor agonist-mediated cardioprotection. Circ Res. 2026;139:e327425. doi: 10.1161\/CIRCRESAHA.126.327425","DOI":"10.1161\/CIRCRESAHA.126.327425"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","unstructured":"Golec S Viadya A Pitt B Jaffe IZ. Mechanisms for mineralocorticoid-driven age-related hypertension: potential therapeutic role of mineralocorticoid receptor antagonists and aldosterone synthase inhibitors. Circ Res. 2026;139:e327593. doi: 10.1161\/CIRCRESAHA.126.327593","DOI":"10.1161\/CIRCRESAHA.126.327593"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.03.005"},{"key":"e_1_3_2_16_2","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome.","volume":"45","author":"Conn JW","year":"1955","unstructured":"Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3\u201317.","journal-title":"J Lab Clin Med"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","unstructured":"Steckelings UM Rossitto G Bader M. Targeting the renin angiotensin aldosterone system: preclinical and clinical developments. Circ Res. 2026;139:e327681. doi: 10.1161\/CIRCRESAHA.126.327681","DOI":"10.1161\/CIRCRESAHA.126.327681"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010016"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","unstructured":"Patel TA Rose J Katsurada K Yada T Salomon J Patel KP Alfaidi M. GLP-1 receptor agonists: from clinical success to mechanistic insight. Circ Res. 2026;139:e327683. doi: 10.1161\/CIRCRESAHA.126.327683","DOI":"10.1161\/CIRCRESAHA.126.327683"}],"container-title":["Circulation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCRESAHA.126.329279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:00:34Z","timestamp":1784224834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCRESAHA.126.329279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,17]]}},"alternative-id":["10.1161\/CIRCRESAHA.126.329279"],"URL":"https:\/\/doi.org\/10.1161\/circresaha.126.329279","relation":{},"ISSN":["0009-7330","1524-4571"],"issn-type":[{"value":"0009-7330","type":"print"},{"value":"1524-4571","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2026-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}